Introduction
============

Breast cancer (BC) is one of the most prevalent types of cancer in women, with \~231,840 new cases and an expected mortality rate of 6.8% in 2015 reported by the National Institutes of Health ([@b1-ol-0-0-5764]). Although there have been numerous advancements in early diagnostic tools, surgical treatments, chemoradiotherapy, hormone therapy and targeted therapy, the prognosis of certain patients with BC remains poor. This may be due to the fact that the probability of BC recurrence following treatment is high ([@b2-ol-0-0-5764],[@b3-ol-0-0-5764]). Therefore, studies investigating the underlying mechanisms of carcinogenesis, progression, and the identification of prognostic markers and potential therapeutic targets for BC are warranted.

Tripartite motif (TRIM) family proteins, which contain a Really Interesting New Gene finger domain, B-box zinc finger domain and a coiled coil region, are considered important regulators of carcinogenesis ([@b4-ol-0-0-5764]). Previously, TRIM family proteins, such as TRIM3, TRIM16, TRIM26 and TRIM31 have been demonstrated to serve a significant role in the tumorigenesis and progression of numerous cancer types ([@b5-ol-0-0-5764]--[@b8-ol-0-0-5764]). TRIM28 (also known as KRAB-associated protein-1 or transcriptional intermediary factor 1β) belongs to the group of TRIM proteins that function as E3 ubiquitin ligases ([@b9-ol-0-0-5764]) and is an essential component of several multiprotein complexes ([@b10-ol-0-0-5764]--[@b12-ol-0-0-5764]). TRIM28 is involved in a wide range of biological processes ([@b13-ol-0-0-5764]--[@b15-ol-0-0-5764]). Several studies have investigated the prognostic value of TRIM28 in different cancer tissues. These studies revealed that upregulation of TRIM28 is associated with poor prognosis in patients with gastric cancer ([@b16-ol-0-0-5764]) and aggressive clinicopathological characteristics in patients with ovarian cancer ([@b17-ol-0-0-5764]), in addition to being a metastatic and prognostic biomarker in early stage non-small cell lung cancer ([@b18-ol-0-0-5764]). Furthermore, a high TRIM28 expression ratio between the stromal and epithelial compartments of colorectal cancer tissue has been demonstrated to be an independent predictor of poor patient prognosis ([@b19-ol-0-0-5764]).

The role of TRIM28 in tumorigenesis is complex and associated with numerous biological processes, including cellular proliferation, invasion, differentiation and senescence ([@b13-ol-0-0-5764]--[@b15-ol-0-0-5764]). Furthermore, a recent study investigating the role of TRIM28 in BC demonstrated that TRIM28 promotes cell proliferation and metastasis through the stimulation of multiple Krüppel-associated box (KRAB) zinc finger domain-containing proteins ([@b12-ol-0-0-5764]).

A growing number of studies have investigated the function of TRIM28; however, the association between TRIM28 expression and the prognosis of patients with BC remains unclear. In the current study, the clinical relevance and prognostic value of TRIM28 in BC was evaluated through bioinformatical analyses.

Materials and methods
=====================

### Utilization of the Gene Expression Omnibus (GEO) database

The GEO database from the National Center for Biotechnology Information (National Institutes of Health, Bethesda, MD, USA) is a public data repository generated predominantly from microarray studies. A total of 16 different GEO datasets were downloaded and 15 of which contained cancerous and healthy tissue sample data were used to analyze the expression of TRIM28 mRNA \[measured as log~2~ (probe intensities)\] in cancer. The basic features of the 15 GEO datasets are illustrated in [Table I](#tI-ol-0-0-5764){ref-type="table"}.

To analyze the association between the expression of TRIM28 and the clinicopathological characteristics of patients with BC, a large cohort of patients with BC (\>100), and their corresponding clinical information and follow-up records were included in the present study. Datasets GSE42568 (n=121) ([@b20-ol-0-0-5764]) and GSE3494 (n=251) ([@b21-ol-0-0-5764]) were chosen for further analysis in the present study. Their clinical information was extracted and analyzed statistically. The tumor sample data from these two datasets was pooled and categorized into two groups according to their expression level of TRIM28 mRNA (top 1/3, high; bottom 2/3, low).

### Construction of the protein-protein interaction (PPI) network

The corresponding TRIM28-associated PPI network was constructed using a web-based bioinformatics tool, Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; version 10.0; <http://string-db.org/>) ([@b22-ol-0-0-5764]). STRING is a database containing known and predicted interactions for proteins, including physical and functional associations obtained from genomic analyses, high-throughput experiments, and co-expression studies. The phrase 'TRIM28' was entered into the STRING database for analysis and PPIs associated with proteins from Homo sapiens were selected. The PPI network was subsequently grown to obtain ≥100 protein interactions and further refined to include only those interactions with a confidence score \>0.9.

### Relapse-free survival analysis

The online database Kaplan-Meier Plotter ([www.kmplot.com](www.kmplot.com)) was used to determine the association between TRIM28 mRNA expression and relapse-free survival (RFS) ([@b23-ol-0-0-5764]). This database includes data from studies on breast ([@b23-ol-0-0-5764]), lung ([@b24-ol-0-0-5764]), ovarian ([@b25-ol-0-0-5764]) and gastric cancer ([@b26-ol-0-0-5764]). Using Kaplan Meier-Plotter, it is currently possible to assess the effect of 54,675 genes on patient survival from the data of 10,188 tumor samples. The BC data on Kaplan Meier-Plotter was obtained from 4,142 patients, with a mean follow-up of 69 months. Briefly, 'TRIM28' or '200990_at' (TRIM28 probe number) were entered into the breast cancer-specific area of the database (<http://kmplot.com/analysis/index.php?p=service&cancer=breast>) to obtain Kaplan-Meier survival curves, in which the number of patients at risk of mortality was reported below the main plot. Hazard ratios (HR) with 95% confidence intervals (CI), and P-values (from the log-rank test) were calculated and displayed on the webpage.

### Statistical analysis

Statistical analysis of significant differences was acquired using the GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). The differences of TRIM28 expression between tumor and non-tumor in 15 datasets were assessed by the Mann-Whitney U test. Pearson\'s χ^2^ test was used to analyze the association between the expression of TRIM28 and the clinicopathological characteristics of patients with BC. A statistically significant difference was considered as P\<0.05.

Results
=======

### TRIM28 is upregulated in multiple tumors

Differences in the expression of TRIM28 mRNA between cancerous and healthy tissue samples from multiple tumor types (GEO datasets) were assessed. As illustrated in [Fig. 1](#f1-ol-0-0-5764){ref-type="fig"}, the expression of TRIM28 was significantly upregulated in BC (P\<0.0001), ovarian cancer (P=0.0407), hepatocellular carcinoma (P\<0.0001), colorectal cancer (P=0.0008), lung cancer (P\<0.0001), esophageal carcinoma (P=0.0001), melanoma (P\<0.0001), nasopharyngeal carcinoma (P=0.0043), gastric cancer (P\<0.0001) and acute lymphoblastic leukemia (P\<0.0001). These results demonstrate that TRIM28 is significantly upregulated in multiple tumor types, indicating that it is involved in the tumorigenesis of these cancers.

### TRIM28 is associated with the clinicopathological characteristics of patients with BC

In order to determine the association between TRIM28 expression and the clinicopathological characteristics of patients with BC, the datasets GSE42568 and GSE3494 were statistically analyzed. As illustrated in [Tables II](#tII-ol-0-0-5764){ref-type="table"} and [III](#tIII-ol-0-0-5764){ref-type="table"}, TRIM28 expression was significantly correlated with patient age (P=0.016), tumor recurrence (P=0.004), p53 mutation status (P=0.002), progesterone receptor (PR) expression status (P=0.014) and Elston grade of the tumor (Nottingham histological score; P=0.001) in BC. These results indicate that TRIM28 effects BC development and recurrence, and the prognosis of patients with BC.

### PPI network of TRIM28

In order to better understand the function, regulatory mechanisms and interactions of TRIM28, the STRING database was used to build a PPI network for TRIM28 ([Fig. 2](#f2-ol-0-0-5764){ref-type="fig"}). A total of 42 predicted functional partners were reported to interact with TRIM28 and each other within the network (all confidence score \>0.9). The greater the number of connections between proteins the stronger the reported association is. Among the 42 predicted PPI network proteins for TRIM28 identified by STRING, several tumor-associated proteins were identified, indicating the tumor-promoting functions of TRIM28. These proteins included the following: Ubiquitin C (UBC); MDM2 proto-oncogene (MDM2); tumor protein p53 (TP53); E2F transcription factor 1 (E2F1); melanoma antigen family (MAGE) C2; and signal transducer and activator of transcription 3 (STAT3).

### Increased TRIM28 expression is associated with poor patient prognosis in BC

The prognostic value of TRIM28 expression was examined using the Kaplan Meier-Plotter database. The same cut-off value was used to categorize patients into low and high expression groups prior to being subjected to survival comparison. Survival curves were plotted for all patients (n=3,554; [Fig. 3A](#f3-ol-0-0-5764){ref-type="fig"}). In addition, further curves were plotted for the following subgroups: Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative BC; n=249; [Fig. 3B](#f3-ol-0-0-5764){ref-type="fig"}); TP53 mutation (n=188; [Fig. 3C](#f3-ol-0-0-5764){ref-type="fig"}); and wild-type TP53 (n=273; [Fig. 3D](#f3-ol-0-0-5764){ref-type="fig"}). Low expression of TRIM28 mRNA was significantly correlated with improved RFS in all patients over 20 years (HR, 1.2; 95% CI, 1.07--1.35; P=0.0026; [Fig. 3A](#f3-ol-0-0-5764){ref-type="fig"}). This was not true in patients who had triple-negative BC, which is possibly due to the relatively low number of patients sampled (HR, 1.53; 95% CI, 0.99--2.37; P=0.0539; [Fig. 3B](#f3-ol-0-0-5764){ref-type="fig"}).

TP53 mutation has previously been associated with poor prognosis in patients with BC ([@b27-ol-0-0-5764]). Low expression of TRIM28 mRNA was significantly correlated with improved RFS in the TP53 mutated (HR, 2.04; 95% CI, 1.27--3.27; P=0.0027; [Fig. 3C](#f3-ol-0-0-5764){ref-type="fig"}) and TP53 wild-type (HR, 1.67; 95% CI, 1.09--2.55; P=0.0174; [Fig. 3D](#f3-ol-0-0-5764){ref-type="fig"}) groups, which indicates that TRIM28 is an independent predictor of poor prognosis in patients with BC.

Tumor genotypes make a significant contribution to selection and response to adjuvant therapies ([@b28-ol-0-0-5764]). In the present study, low expression of TRIM28 was significantly correlated with improved RFS in patients with tumors that were ER-positive (HR, 1.2; 95% CI, 1--1.43; P=0.0462; [Fig. 4A](#f4-ol-0-0-5764){ref-type="fig"}), PR-positive (HR, 1.69; 95% CI, 1.18--2.43; P=0.0039; [Fig. 4C](#f4-ol-0-0-5764){ref-type="fig"}) or HER2-negative (HR, 1.4; 95% CI, 1.06--1.83; P=0.0154; [Fig. 4F](#f4-ol-0-0-5764){ref-type="fig"}), which suggests that TRIM28 is a prognostic marker in patients with different phenotypes of BC.

To determine the association between TRIM28 expression and prognostic features, the association between TRIM28 and Elston grade, lymph node status, endocrine therapy use and chemotherapy use in patients with BC was investigated ([Table IV](#tIV-ol-0-0-5764){ref-type="table"}). High expression of TRIM28 was significantly correlated with Elston grade I (HR, 1.98; 95% CI, 1.14--3.41; P=0.0127) and III (HR, 1.37; 95% CI, 1.06--1.76; P=0.0142) tumors, but not Elston grade II tumors (HR, 1.13; 95% CI, 0.86--1.48; P=0.3734). In addition, high expression of TRIM28 was significantly correlated with patients who had received endocrine therapy (HR, 1.54; 95% CI, 1.19--1.98; P=0.0008), chemotherapy (HR, 2.14; 95% CI, 1.51--3.02; P=1×10^−5^), and the patients who had not received chemotherapy (HR, 1.21; 95% CI, 1.02--1.43; P=0.0253).

Discussion
==========

Proteins in the TRIM family serves a role in various physiological functions through activating or suppressing their corresponding molecules, including cell cycle regulators, checkpoint molecules, apoptosis-associated factors and tumor-promoting or inhibiting factors ([@b9-ol-0-0-5764],[@b29-ol-0-0-5764]). Several previous studies have demonstrated that TRIM family proteins function in BC development and progression, including the following: TRIM22, which is underexpressed in BC due to p53 dysfunction ([@b30-ol-0-0-5764]); TRIM24, which is a viable therapeutic target for the treatment of patients with BC through reprogramming of glucose metabolism ([@b31-ol-0-0-5764]); and TRIM29, which functions as a tumor suppressor, as loss of TRIM29 expression in breast luminal cells can lead to the progression of ER-positive BC in premenopausal women ([@b32-ol-0-0-5764]). In addition, a recent study investigating the role of TRIM28 in BC demonstrated that TRIM28 promotes BC cell proliferation and metastasis by stimulating multiple KRAB family zinc finger domain-containing proteins ([@b12-ol-0-0-5764]). TRIM28 expression has been correlated with poor patient prognosis in various cancers, including gastric, ovarian, colorectal and lung ([@b16-ol-0-0-5764]--[@b19-ol-0-0-5764]). However, to the best of our knowledge, the prognostic value of TRIM28 expression in BC has not been investigated.

In the present study, the clinical relevance and prognostic value of TRIM28 in BC was investigated. The results of the present study revealed that TRIM28 expression was associated with the survival of patient with BC. In addition, expression of TRIM28 was significantly elevated in multiple tumor types, including BC, when compared with matched healthy tissue samples, suggesting that TRIM28 serves a role in tumorigenesis. Furthermore, it was demonstrated that TRIM28 mRNA expression was significantly associated with tumor recurrence, TP53 mutation status, PR expression status and Elston grade of the tumor in patients with BC. These results indicate that TRIM28 promotes BC progression, as TP53 mutation-correlated genes have been reported to predict the risk of tumor relapse ([@b33-ol-0-0-5764]).

The PPI network provides a better understanding of the functional associations between TRIM28 and other proteins. Among the 42 predicted functional partner proteins identified using the STRING database, several tumor-associated proteins, such as UBC, MDM2, TP53, E2F1, MAGEC2 and STAT3 were identified. Ubiquitination has been associated with protein degradation, DNA repair and cell cycle regulation ([@b34-ol-0-0-5764]--[@b36-ol-0-0-5764]). A previous study demonstrated that the downregulation of UBC inhibits the proliferation and radioresistance of non-small cell lung cancer cells ([@b37-ol-0-0-5764]). In addition, another study identified that MAGEA-TRIM28 functions as an oncogene ([@b38-ol-0-0-5764]). MDM2 is a non-redundant inhibitor of p53 ([@b39-ol-0-0-5764],[@b40-ol-0-0-5764]) and has been demonstrated to promote cell proliferation in BC through a p53-independent mechanism ([@b41-ol-0-0-5764]). p53, a tumor suppressor, regulates the cell cycle, apoptosis, senescence and autophagy, and contributes to mammary gland development and BC progression ([@b42-ol-0-0-5764]). TRIM28 inhibits p53 acetylation and promotes the ubiquitination of p53 ([@b43-ol-0-0-5764],[@b44-ol-0-0-5764]). E2F1 mediates cell proliferation and p53-dependent cell apoptosis, and its negative regulation by TRIM28 may serve as a backup mechanism to prevent E2F1-mediated cell apoptosis ([@b45-ol-0-0-5764]). MAGEC2 promotes the phosphorylation of TRIM28 ([@b46-ol-0-0-5764]). MAGEC proteins form a complex with TRIM28 and suppress p53-dependent apoptosis in MAGE-positive cell lines ([@b47-ol-0-0-5764]). STAT3 mediates the cellular response to interleukins and other growth factors. Deregulation of STAT3 activity is associated with a range of cancer types and TRIM28 has been demonstrated to inactivate STAT3 ([@b48-ol-0-0-5764]).

Patients with triple-negative BC typically have high-grade tumors and a poor prognosis ([@b49-ol-0-0-5764],[@b50-ol-0-0-5764]). Thus, the association between TRIM28 expression and RFS in patients with triple-negative BC was evaluated in the present study. Although no significant association between these factors was detected, the low TRIM28 expression group demonstrated a markedly increased RFS compared with the high expression group. TP53 mutations in BC have been associated with poor patient prognosis ([@b27-ol-0-0-5764]). The results of the present study suggest that TRIM28 is an independent prognostic factor in patients with mutated and wild-type TP53 BC.

The identification of therapeutic targets in cancer tissue is essential in order to select the most appropriate anti-cancer drugs. In the case of BC, ER, PR and HER2 expression analysis has been a routine clinical practice for years, and has made a significant contribution to the drug selection process and tumor response to adjuvant therapies ([@b28-ol-0-0-5764]). ER/PR expression status guides the selection of hormone therapies for BC ([@b51-ol-0-0-5764]) and HER2 expression status is a predictive marker for the response of patients with BC to trastuzumab ([@b52-ol-0-0-5764]). In the present study, low expression of TRIM28 was significantly correlated with improved RFS in the ER-positive, HER2-negative and PR-positive expression groups. Therefore, therapeutic targeting of TRIM28 may improve patient outcome. In addition, the findings of the current study demonstrated that TRIM28 expression was significantly associated with Elston grade of the tumor. Furthermore, the results of the present study indicate that high expression of TRIM28 is a risk factor for BC recurrence in patients who have received endocrine therapy, and patients who have or have not received chemotherapy.

In conclusion, the present study demonstrated the clinical relevance and prognostic value of TRIM28 in patients with BC. TRIM28 is frequently elevated in multiple tumor types and is associated with aggressive clinical features of BC. The PPI network created revealed that TRIM28 may interact with other oncogenes to serve a role in BC progression. Furthermore, the overexpression of TRIM28 was significantly correlated with poor prognosis in patients with BC, suggesting that TRIM28 is a prognostic marker and potential therapeutic target in patients with BC.

![TRIM28 expression in cancer. TRIM28 expression was significantly elevated in the majority of tumor tissues compared with healthy tissue samples, from 15 publicly available Gene Expression Omnibus datasets. TRIM28 expression was measured as log~2~ (probe intensities), and presented as mean ± standard error of the mean. \*P\<0.05; \*\*\*P\<0.001. TRIM28, tripartite motif containing 28; BC, breast cancer; OSE, ovarian surface epithelia samples; ccRCC, clear-cell Renal cell carcinoma; ESCC, esophageal squamous cell carcinoma; PBMCs, peripheral blood mononuclear cells.](ol-13-04-2670-g00){#f1-ol-0-0-5764}

![Protein-protein interaction network for tripartite motif containing 28 protein. Different colored lines represent the types of evidence for the association. The purple, light blue and light green colored lines represent evidence from databases, experiments and text mining, respectively.](ol-13-04-2670-g01){#f2-ol-0-0-5764}

![Prognostic value of TRIM28 expression in patients with BC. TRIM28 probe number is 200990_at. Survival curves for (A) all patients with BC combined (n=3554), (B) triple-negative BC patients (n=249), (C) TP53 mutated BC cases (n=188) and (D) wild-type TP53 BC cases (n=273). Results were analyzed using the Kaplan-Meier Plotter database. 'Probability' on the y-axes is referring to the relapse free survival rates. 'Number at risk' under the x-axes is referring to the number of BC survivors who were in the risk of a recurrence at a certain point in time. HR values were presented as HR=mean (95% CI). The generated P-value does not include correction for multiple hypothesis testing by default. TRIM28, tripartite motif containing 28; TP53, tumor protein p53; HR, hazard ratio; CI, confidence intervals; BC, breast cancer.](ol-13-04-2670-g02){#f3-ol-0-0-5764}

![Prognostic value of TRIM28 expression in different BC genotypes. TRIM28 probe number is 200990_at. Survival curves for (A) ER-positive (n=1802), (B) ER-negative (n=671), (C) PR-positive (n=525), (D) PR-negative (n=483), (E) HER2-positive (n=168) and (F) HER2-negative (n=756) BC cases. Results were analyzed using the Kaplan-Meier Plotter database. 'Probability' on the y-axes is referring to the relapse free survival rates. 'Number at risk' under the x-axes is referring to the number of BC survivors who were in the risk of a recurrence at a certain point in time. HR values were presented as HR=mean (95% CI). The generated P-value does not include correction for multiple hypothesis testing by default. TRIM28, tripartite motif containing 28; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence intervals; BC, breast cancer.](ol-13-04-2670-g03){#f4-ol-0-0-5764}

###### 

Basic features of the 15 Gene Expression Omnibus datasets.

  Cancer type                    Accession number   Number of samples (tumor/control)   P-value
  ------------------------------ ------------------ ----------------------------------- ----------
  Breast                         GSE42568           104/17                              \<0.0001
  Ovarian                        GSE14407           12/12                               0.0407
  Hepatocellular carcinoma       GSE14520           214/214                             \<0.0001
  Colorectal                     GSE32323           17/17                               0.0008
  Renal clear cell carcinoma     GSE36895           23/23                               0.4799
  Prostate                       GSE6919            56/56                               0.1584
  Lung                           GSE30219           293/14                              \<0.0001
  Esophageal carcinoma           GSE20347           17/17                               0.0001
  Pancreatic                     GSE28735           45/45                               0.8424
  Melanoma                       GSE3189            45/25                               \<0.0001
  Nasopharyngeal carcinoma       GSE12452           31/10                               0.0043
  Gastric                        GSE13911           31/31                               \<0.0001
  Acute lymphoblastic leukemia   GSE26713           117/7                               \<0.0001
  Papillary thyroid carcinoma    GSE3467            9/9                                 0.5215
  Myeloma                        GSE27838           16/16                               0.3133

P-values were obtained through the Mann-Whitney U test for the comparison of TRIM28 expression between tumor and control.

###### 

Correlation between TRIM28 expression and the clinicopathological characteristics of patients with breast cancer in GSE42568.

                               TRIM28 expression                 
  ----------------------- ---- ------------------- ----- ------- -------
  Age (years old)                                        5.797   0.016
    ≤50                   27     4                 23            
    \>50                  77   31                  46            
  ER expression status                                   1.187   0.276
    Positive              67   25                  42            
    Negative              34     9                 25            
  Tumor size (cm)                                        2.813   0.093
    \<2                   18     3                 15            
    ≥2                    86   32                  54            
  Elston grade                                           3.454   0.178
    I                     11     3                   8           
    II                    40     8                 32            
    III                   53   24                  29            
  Lymph node metastasis                                  1.734   0.188
    Yes                   59   23                  36            
    No                    45   12                  33            
  Tumor recurrence                                       8.122   0.004
    Yes                   48   23                  25            
    No                    56   12                  44            

The top 1/3 of patients with the highest TRIM28 expression were defined as the high-expression group and the bottom 2/3 were defined as the low-expression group. P-values were obtained through the Pearson χ^2^ test for the comparison of the two groups (high vs. low) in different clinicopathological characteristics of patients with BC. ER, estrogen receptor; TRIM28, tripartite motif containing 28.

###### 

Correlation between TRIM28 expression and the clinicopathological characteristics of patients with breast cancer in GSE3494.

                                 TRIM28 expression                    
  ----------------------- ------ ------------------- ------ --------- -------
  Age (years old)                                             0.346   0.557
    ≤50                     55   20                    35             
    \>50                  196    63                  133              
  TP53 mutation status                                        9.771   0.002
    Positive                58   29                    29             
    Negative              193    54                  139              
  ER expression status                                        1.954   0.162
    Positive              213    68                  145              
    Negative                34   15                    19             
  PR expression status                                        5.997   0.014
    Positive              190    55                  135              
    Negative                61   28                    33             
  Elston grade                                              14.200    0.001
    I                       67   13                    54             
    II                    128    42                    86             
    III                     54   28                    26             
  Tumor size (cm)                                             2.654   0.103
    \<2                   112    31                    81             
    ≥2                    139    52                    87             
  Lymph node metastasis                                       0.410   0.522
    Yes                     84   30                    54             
    No                    158    50                  108              

The top 1/3 of patients with the highest TRIM28 expression were defined as the high-expression group and the bottom 2/3 were defined as the low-expression group. P-values were obtained through the Pearson chi-square test for the comparison of the two groups (high vs. low) in different clinicopathological characteristics of patients with BC. ER, estrogen receptor; PR, progesterone receptor; TRIM28, tripartite motif containing 28; TP53, tumor protein p53.

###### 

Correlation between TRIM28 expression and prognostic factors in patients with breast cancer.

  Prognostic factor            Number of cases   HR     95% CI       P-value
  ---------------------------- ----------------- ------ ------------ -----------
  Elston grade                                                       
    I                          308               1.98   1.14--3.41   0.0127
    II                         724               1.13   0.86--1.48   0.3734
    III                        723               1.37   1.06--1.76   0.0142
  Lymph node metastasis                                              
    Yes                        945               1.25   1-1.57       0.0514
    No                         1813              1.11   0.93--1.33   0.2542
  Endocrine therapy received                                         
    Yes                        999               1.54   1.19--1.98   0.0008
    No                         1401              1.16   0.96--1.4    0.1341
  Chemotherapy received                                              
    Yes                        425               2.14   1.51--3.02   1×10^−05^
    No                         1974              1.21   1.02--1.43   0.0253

Results were analyzed using the Kaplan-Meier Plotter database. P-values were obtained through the log-rank test from the website to compare the relapse free survival rates related to TRIM28 expression. The generated P-value does not include correction for multiple hypotheses testing by default. HR, hazard ratio; CI, confidence interval; TRIM28, tripartite motif containing 28.

[^1]: Contributed equally
